Table 3.
Change in 25(OH)D, PTH, blood pressure, lipids and measures of glucose metabolism
| Vitamin D | Placebo | Between group | |||||
|---|---|---|---|---|---|---|---|
| Baseline (n=30)a | Change (n=29)a | P-valueb | Baseline (n=15)a | Change (n=15)a | P-valueb | P-valuec | |
| 25(OH)D, ng/ml | 9.0(7.1–13.1) | 5.0 (−0.9–7.4) | 0.002 | 6.2 (3.7–9.8) | −1.8 (−2.9–0.1) | 0.097 | 0.018 |
| PTH in responders, pg/ml (n=15)d | 74 (47–89) | −15 (−33–1.0) | 0.016 | 62 (44–93) | −4.0 (−21.0–4.0) | 0.165 | 0.216 |
| PTH in non-responders, pg/ml (n=14)d | 68(55–91) | −22 (−33–3.0) | 0.016 | ||||
| Systolic blood pressure, mmHg | 118(106–125) | 1.5 (−9.5–10.5) | 0.845 | 120(108–128) | 0 (−17–12) | 0.636 | 0.620 |
| Diastolic blood pressure, mmHg | 80 (72–83) | −3.0 (−4.0–4.0) | 0.498 | 80 (72–88) | −6.0 (−10.0–6.0) | 0.217 | 0.377 |
| Total cholesterol, mg/dl | 191 (157–224) | −9. 0 (−25.0–4.0) | 0.009 | 189(155–232) | −1.0 (−18–12) | 0.528 | 0.281 |
| HDL cholesterol, mg/dl | 41 (36–51) | −1.0 (−5.0–3.0) | 0.249 | 48 (39–56) | −1.0 (−7.0–3.0) | 0.237 | 0.901 |
| Non-HDL cholesterol, mg/dl | 154(115–183) | −7.0 (−21.0–8.0) | 0.022 | 146 (94–195) | −2.0 (−11–11) | 0.968 | 0.249 |
| Triglycerides, mg/dl | 156(95–243) | 20 (−19–57) | 0.051 | 99 (58–202) | 7.0 (−31–35) | 0.833 | 0.169 |
| HOMA-IR | 2.1 (1.0–3.6) | 0.8(0.3–1.9) | <0.0001 | 1.9(1.0–2.9) | 0.3 (−0.2–0.7) | 0.217 | 0.130 |
| Insulin, µlU/ml | 10(5–16) | 4 (0–6.0) | 0.0007 | 8.5(5–15) | 1.5 (−2.0–5.0) | 0.457 | 0.227 |
| Glucose, mg/dl | 84 (77–90) | 0 (−4.0–9.0) | 0.355 | 78 (69–92) | −2.0 (−13.0–7.0) | 0.572 | 0.310 |
Values in bold indicate statistical significance (P<0.05).
a
Date are presented as median (IQR).
b
P-value for within-group change.
c
P-value comparing D change versus placebo change; for parathyroid hormone (PTH), all vitamin D (n=29) is compared with placebo.
d
Response was defined as a rise in 25-hydroxyvitamin D (25[OH]D) level ≥5 ng/ml from baseline to follow-up among participants taking vitamin D. HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance.